Arrowhead price target raised to $80 from $60 at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio raised the firm’s price target on Arrowhead (ARWR) to $80 from $60 and keeps a Buy rating on the ...
Muscular Dystrophy News4h
Sarepta to develop Arrowhead’s muscular dystrophy treatments
Sarepta has acquired the global rights to develop ARO-DUX4 and ARO-DM1, two RNAi therapeutic candidates for types of muscular ...
ARWR: License and Collaboration Deal with Sarepta Includes $825 Million Upon Closing…
ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Collaboration Deal with Sarepta Includes $825 Million Upon Closing On November 26, 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced ...
Sarepta Therapeutics: Sell Rating Amid Uncertain Pipeline and Financial Risks
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and decreased the price ...
BioSpace1d
FDA’s Accelerated Approval Pathway Drives Momentum for Intractable, Fatal Diseases
Despite hotly debated biomarkers and failed or delayed confirmatory trials, the accelerated approval program has a track ...
Business Wire3d
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on November 29, 2024 (the ...
bovnews3d
SRPT Unveiled: The Shocking Truth Behind Sarepta Therapeutics Inc’s Latest Stock Movements
On Wednesday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $137.94 which represents a slight increase of $7.44 or 5.70% from the prior close of $130.5. The stock opened ...
Zacks.com on MSN4d
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?
Shares of Sarepta Therapeutics SRPT have soared 43% year to date, significantly outperforming the industry’s 6.9% decline.
Investor's Business Daily on MSN4d
Sarepta Therapeutics Sees RS Rating Rise To 75
A Relative Strength Rating upgrade for Sarepta Therapeutics shows improving technical performance. Will it continue?
What is HC Wainwright’s Forecast for SRPT FY2024 Earnings?
Analysts at HC Wainwright issued their FY2024 EPS estimates for Sarepta Therapeutics in a research note issued to investors ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Purchased by Commerce Bank
Commerce Bank boosted its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 15.7% in the 3rd quarter, ...